192 related articles for article (PubMed ID: 1384424)
1. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion.
Nakashima H; Masuda M; Murakami T; Koyanagi Y; Matsumoto A; Fujii N; Yamamoto N
Antimicrob Agents Chemother; 1992 Jun; 36(6):1249-55. PubMed ID: 1384424
[TBL] [Abstract][Full Text] [Related]
2. A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II).
Masuda M; Nakashima H; Ueda T; Naba H; Ikoma R; Otaka A; Terakawa Y; Tamamura H; Ibuka T; Murakami T
Biochem Biophys Res Commun; 1992 Dec; 189(2):845-50. PubMed ID: 1472056
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), determined by nuclear magnetic resonance.
Tamamura H; Kuroda M; Masuda M; Otaka A; Funakoshi S; Nakashima H; Yamamoto N; Waki M; Matsumoto A; Lancelin JM
Biochim Biophys Acta; 1993 May; 1163(2):209-16. PubMed ID: 8490053
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of an anti-HIV peptide, T22.
Tamamura H; Murakami T; Masuda M; Otaka A; Takada W; Ibuka T; Nakashima H; Waki M; Matsumoto A; Yamamoto N
Biochem Biophys Res Commun; 1994 Dec; 205(3):1729-35. PubMed ID: 7811258
[TBL] [Abstract][Full Text] [Related]
5. Molecular parameters for the anti-human immunodeficiency virus activity of T22 ([Tyr5,12, Lys7]-polyphemusin II).
Otaka A; Tamamura H; Terakawa Y; Masuda M; Koide T; Murakami T; Nakashima H; Matsuzaki K; Miyajima K; Ibuka T
Biol Pharm Bull; 1994 Dec; 17(12):1669-72. PubMed ID: 7735216
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of tachyplesin I on the proliferation of human immunodeficiency virus in vitro.
Morimoto M; Mori H; Otake T; Ueba N; Kunita N; Niwa M; Murakami T; Iwanaga S
Chemotherapy; 1991; 37(3):206-11. PubMed ID: 1889308
[TBL] [Abstract][Full Text] [Related]
7. Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II).
Tamamura H; Arakaki R; Funakoshi H; Imai M; Otaka A; Ibuka T; Nakashima H; Murakami T; Waki M; Matsumoto A; Yamamoto N; Fujii N
Bioorg Med Chem; 1998 Feb; 6(2):231-8. PubMed ID: 9547946
[TBL] [Abstract][Full Text] [Related]
8. Downsizing of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II), with the maintenance of anti-HIV activity and solution structure.
Tamamura H; Waki M; Imai M; Otaka A; Ibuka T; Waki K; Miyamoto K; Matsumoto A; Murakami T; Nakashima H; Yamamoto N; Fujii N
Bioorg Med Chem; 1998 Apr; 6(4):473-9. PubMed ID: 9597190
[TBL] [Abstract][Full Text] [Related]
9. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.
Xu Y; Tamamura H; Arakaki R; Nakashima H; Zhang X; Fujii N; Uchiyama T; Hattori T
AIDS Res Hum Retroviruses; 1999 Mar; 15(5):419-27. PubMed ID: 10195751
[TBL] [Abstract][Full Text] [Related]
10. The synthetic [Tyr5,12,Lys7]-polyphemusin II peptide (T22) binds to the CD4 cell surface molecule.
Weeks BS; Nomizu M; Otaka A; Weston CA; Okusu A; Tamamura H; Yamamoto N; Fujii N
Biochem Biophys Res Commun; 1995 Oct; 215(2):626-31. PubMed ID: 7488001
[TBL] [Abstract][Full Text] [Related]
11. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection.
Tamamura H; Imai M; Ishihara T; Masuda M; Funakoshi H; Oyake H; Murakami T; Arakaki R; Nakashima H; Otaka A; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N
Bioorg Med Chem; 1998 Jul; 6(7):1033-41. PubMed ID: 9730240
[TBL] [Abstract][Full Text] [Related]
12. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection.
De Clercq E
Med Res Rev; 2000 Sep; 20(5):323-49. PubMed ID: 10934347
[TBL] [Abstract][Full Text] [Related]
13. Interaction of an anti-HIV peptide, T22, with gp120 and CD4.
Tamamura H; Otaka A; Murakami T; Ishihara T; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N
Biochem Biophys Res Commun; 1996 Feb; 219(2):555-9. PubMed ID: 8605026
[TBL] [Abstract][Full Text] [Related]
14. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection.
Murakami T; Nakajima T; Koyanagi Y; Tachibana K; Fujii N; Tamamura H; Yoshida N; Waki M; Matsumoto A; Yoshie O; Kishimoto T; Yamamoto N; Nagasawa T
J Exp Med; 1997 Oct; 186(8):1389-93. PubMed ID: 9334379
[TBL] [Abstract][Full Text] [Related]
15. [A synthetic peptide "T22" as anti-HIV agents].
Nakashima H; Murakami T
Nihon Rinsho; 1993 Sep; 51 Suppl():146-52. PubMed ID: 8271378
[No Abstract] [Full Text] [Related]
16. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.
Murakami T; Zhang TY; Koyanagi Y; Tanaka Y; Kim J; Suzuki Y; Minoguchi S; Tamamura H; Waki M; Matsumoto A; Fujii N; Shida H; Hoxie JA; Peiper SC; Yamamoto N
J Virol; 1999 Sep; 73(9):7489-96. PubMed ID: 10438838
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial peptides, isolated from horseshoe crab hemocytes, tachyplesin II, and polyphemusins I and II: chemical structures and biological activity.
Miyata T; Tokunaga F; Yoneya T; Yoshikawa K; Iwanaga S; Niwa M; Takao T; Shimonishi Y
J Biochem; 1989 Oct; 106(4):663-8. PubMed ID: 2514185
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the interaction of an anti-HIV peptide, T22 ([Tyr5, 12, Lys7]-polyphemusin II), with gp120 and CD4 by surface plasmon resonance.
Tamamura H; Ishihara T; Otaka A; Murakami T; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N
Biochim Biophys Acta; 1996 Nov; 1298(1):37-44. PubMed ID: 8948487
[TBL] [Abstract][Full Text] [Related]
19. Lymphocytes and promonocytes attach to the synthetic [Tyr5,12, Lys7]- polyphemusin II peptide.
Weeks BS; Nomizu M; Otaka A; Weston CA; Okusu A; Tamamura H; Matsumoto A; Yamamoto N; Fujii N
Biochem Biophys Res Commun; 1994 Jul; 202(1):470-5. PubMed ID: 8037749
[TBL] [Abstract][Full Text] [Related]
20. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.
Wild CT; Shugars DC; Greenwell TK; McDanal CB; Matthews TJ
Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9770-4. PubMed ID: 7937889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
